Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559827 | 1.00 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL9355970 | 0.91 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL9355975 | 0.91 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL15163748 | 0.86 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL1620755 | 0.85 | MAPT (0.67) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL7060516 | 0.85 | MAPT (0.67) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL1620754 | 0.85 | MAPT (0.67) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL560287 | 0.84 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Potassium Ion SCHEMBL560288 | 0.84 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Juarezic Acid SCHEMBL144680 | 0.83 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139056-A1 | METHODS, COMPOSITIONS AND REAGENTS FOR PREPARING COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139056-A1 | METHODS, COMPOSITIONS AND REAGENTS FOR PREPARING COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-05-04 | — | — | US | disclosed |
| EP-2812931-B1 | ELECTRONIC DEVICES COMPRISING PHOTOCURABLE POLYMERIC MATERIALS | FLEXTERRA INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9171961-B2 | Coating materials for oxide thin film transistors | POLYERA CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-9171961-B2 | Coating materials for oxide thin film transistors | POLYERA CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-8878169-B2 | Photocurable polymeric materials and related electronic devices | POLYERA CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| US-8878169-B2 | Photocurable polymeric materials and related electronic devices | POLYERA CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140021465-A1 | Coating Materials for Oxide Thin Film Transistors | FLEXTERRA, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140021465-A1 | Coating Materials for Oxide Thin Film Transistors | FLEXTERRA, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2014011935-A1 | COATING MATERIALS FOR OXIDE THIN FILM TRANSISTORS | POLYERA CORPORATION (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20050107348-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1408946-A4 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | HDAC3 16/4885HDAC4 28/4885HDAC1 6/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 7/4885HDAC4 14/4885HDAC1 1/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 7/4885HDAC4 14/4885HDAC1 1/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885 |
| US-20050107348-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | HDAC3 6/4885HDAC4 15/4885HDAC1 1/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | HDAC3 5/4885HDAC4 13/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.